Skip Navigation


JAC Advance Access originally published online on January 15, 2008
Journal of Antimicrobial Chemotherapy 2008 61(3):757-758; doi:10.1093/jac/dkm528
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/3/757    most recent
dkm528v2
dkm528v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pournaras, S.
Right arrow Articles by Tsakris, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pournaras, S.
Right arrow Articles by Tsakris, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam

Spyros Pournaras1,*, Alexandros Ikonomidis1, Evangelia Neou1, Maria Kantzanou1, Antonios N. Maniatis1 and Athanassios Tsakris2

1 Department of Microbiology, Medical School, University of Thessaly, Larissa, Greece 2 Department of Microbiology, Medical School, University of Athens, Athens, Greece

* Correspondence address. Department of Medical Microbiology, University Hospital of Larissa, Mezourlo, 411 10 Larissa, Greece. Tel: +30-2410-682537; Fax: +30-2410-681570; E-mail: pournaras@med.uth.gr

Keywords: population analysis , time–kill , heteroresistance , persisters , β-lactams , heterogeneity

The first 10% of the full text of this article appears below.

Sir,

Pseudomonal infections have limited therapeutic options due to the intrinsic resistance of the microorganism and its ability to integrate further resistance mechanisms.1 Although antipseudomonal β-lactams such as carbapenems and piperacillin/tazobactam still remain clinically useful, carbapenem-heteroresistant mutants of Pseudomonas aeruginosa have recently been described.2 We wish to further report the occurrence of an isolate showing heteroresistance to piperacillin/tazobactam.

P. aeruginosa strain 7171 (PA7171) was isolated in November 2006 from a urinary tract infection sample of a 38-year-old male who was hospitalized for 7 days at . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?